Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 4Tumor-Agnostic 2Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

pembrolizumab 26Specimen Handling 22Biopsy 22Magnetic Resonance Spectroscopy 20Paclitaxel 12Carboplatin 10Blood Specimen Collection 10Bevacizumab 10atezolizumab 9Standard of Care 9Nivolumab 9Cisplatin 8Radiosurgery 7Pemetrexed 7Gemcitabine 6Cyclophosphamide 6Capecitabine 6trastuzumab deruxtecan 5durvalumab 5X-Rays 5Taxes 5Surveys and Questionnaires 5Irinotecan 5Fluorouracil 5olaparib 4niraparib 4cabozantinib 4Radiotherapy 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
ceritinib × Tumor-Agnostic × 90 days × Clear all
NCT02321501 2026-05-20

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
37 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT02584933 2026-04-02

Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

Novartis

Phase 4 Active not recruiting
233 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡